These conditions often result in organ failure due to myofibroblast activation, scarring, and tissue inflammation. Ono will work alongside Mediar to utilise its fibrosis-focused discovery platform, expertise in
This collaboration will focus on utilising Evotec’s data-driven discovery platform alongside its AI data science and advanced screening technologies. It aims to accelerate the discovery and validation of
The decision affects Replimune’s lead product candidate, which is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response. During the IGNYTE trial,
Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix’s expertise in radiopharmaceutical platforms, global
This agreement will involve the development and commercialisation of the anaesthetic intended for managing postoperative pain. The deal includes $5m upfront to AmacaThera and up to $225m in
Sativex is indicated for the enhancement of symptoms in adult patients experiencing moderate to severe spasticity due to multiple sclerosis (MS) who have not responded sufficiently to other
This topical, steroid-free formulation is applied once daily and can be used for long-term disease control without limits on duration or body surface area. Clinical trials have shown
The agreement covers Samsung Bioepis’ two ophthalmology assets, Byooviz (ranibizumab) and Opuviz (aflibercept), in Europe. The transfer returns commercial rights for Byooviz to Samsung Bioepis and positions the
This tripartite agreement leverages expertise in cell immunotherapies, peptide HLA (pHLA) binder discovery, and bispecific T cell engagers, with the aim of overcoming challenges to achieving durable cancer
Following expansion, the site will cover over 200,000ft² and feature new technologies in sustainably designed facilities. The initial phase of expansion comprises a 31,000ft² building that will accommodate
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.